| DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference – ESOC 2025 |
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today a poster presentation of the safety and clinical outcomes for ReMEDy2 study, the planned pivotal phase 2/3 trial of DM199 in AIS patients, at the 11th European Stroke Organisation Conference – ESOC 2025 being held in Helsinki, Finland from May 21-23, 2025. For information about the event, visit:. |
businesswire.com |
2025-05-14 20:30:00 |
Czytaj oryginał (ang.) |
| DiaMedica Therapeutics Inc. (DMAC) Q1 2025 Earnings Call Transcript |
DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q1 2025 Earnings Conference Call May 14, 2025 8:00 AM ET Company Participants Rick Pauls - President and Chief Executive Officer Scott Kellen - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Matthew Caufield - H.C. Wainwright Chase Knickerbocker - Craig-Hallum Operator Good morning ladies and gentlemen, and welcome to the DiaMedica Therapeutics First Quarter 2025 Conference Call. |
seekingalpha.com |
2025-05-14 15:05:31 |
Czytaj oryginał (ang.) |
| DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights |
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke and preeclampsia, today provided a business update and financial results for the quarter ended March 31, 2025. Management will host a conference call Wednesday, May 14, 2025, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and first quarter 2025 financial results. Preeclampsia Phase 2 C. |
businesswire.com |
2025-05-13 20:30:00 |
Czytaj oryginał (ang.) |
| DiaMedica Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update May 14, 2025 |
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its first quarter 2025 financial results will be released after the markets close on Tuesday, May 13th. DiaMedica will host a live conference call on Wednesday, May 14th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details:. |
businesswire.com |
2025-05-07 12:30:00 |
Czytaj oryginał (ang.) |
| DiaMedica Therapeutics Inc. (DMAC) Q4 2024 Earnings Call Transcript |
DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q4 2024 Earnings Conference Call March 18, 2025 8:00 AM ET Company Participants Rick Pauls - President and CEO Lorianne Masuoka - CMO Scott Kellen - CFO Conference Call Participants Thomas Flaten - Lake Street Chase Knickerbocker - Craig-Hallum Matthew Caufield - H.C. Wainwright Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Full Year 2024 Conference Call. |
seekingalpha.com |
2025-03-18 12:27:40 |
Czytaj oryginał (ang.) |
| DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results |
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke and preeclampsia, today provided a business update and financial results for the year ended December 31, 2024. Management will host a conference call Tuesday, March 18, 2025, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and full year 2024 financial results. “We made significant progr. |
businesswire.com |
2025-03-17 18:30:00 |
Czytaj oryginał (ang.) |
| DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025 |
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that its full-year 2024 financial results will be released after the markets close on Monday, March 17th. DiaMedica will host a live conference call on Tuesday, March 18th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Tuesday, M. |
businesswire.com |
2025-03-11 10:23:00 |
Czytaj oryginał (ang.) |
| DiaMedica Therapeutics Appoints Daniel J. O'Connor to the Board of Directors |
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and preeclampsia, today announced the election of Daniel J. O'Connor to its Board of Directors, effective February 20, 2025. Mr. O'Connor has decades of executive experience and leadership in the biopharmaceutical industry, including as CEO and other executive level leadership positions at Ambrx Biopharma, Inc. (Ambrx), ImClone Systems Incorporate. |
businesswire.com |
2025-02-24 10:30:00 |
Czytaj oryginał (ang.) |
| DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference |
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company's management will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12th, 2025 at 11:20am Eastern Time. Investors and attendees that would like to schedule a meeting with DiaMedica's management can contact their Oppenheimer representative to a. |
businesswire.com |
2025-02-10 18:15:00 |
Czytaj oryginał (ang.) |
| DiaMedica Therapeutics Inc. (DMAC) Q3 2024 Earnings Call Transcript |
DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ET Company Participants Rick Pauls - President, Chief Executive Officer & Director Scott Kellen - Chief Financial Officer & Company Secretary Lorianne Masuoka - Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Chase Knickerbocker - Craig-Hallum Matthew Caufield - H.C. Wainwright Operator Good morning ladies and gentlemen and welcome to the DiaMedica Therapeutics Third Quarter 2024 Conference Call. |
seekingalpha.com |
2024-11-14 14:49:10 |
Czytaj oryginał (ang.) |
| DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results |
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today provided a business update and financial results for the quarter ended September 30, 2024. Management will host a conference call Thursday, November 14, 2024, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and third quarter 2024 financial results. Updates to ReMEDy2 Acute Isc. |
businesswire.com |
2024-11-13 18:20:00 |
Czytaj oryginał (ang.) |
| DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia |
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced that the first patient has been dosed in DiaMedica's investigator-sponsored Phase 2 trial of DM199 for the treatment of preeclampsia (PE). DiaMedica anticipates top line data for Part 1A in the first half of 2025 which is expected to demonstrate initial proof-of-concept including whether DM199 is. |
businesswire.com |
2024-11-13 18:05:00 |
Czytaj oryginał (ang.) |
| DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024 |
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that its third quarter 2024 financial results will be released after market close on Wednesday, November 13th. DiaMedica will host a live conference call on Thursday, November 14th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: T. |
businesswire.com |
2024-11-06 10:32:00 |
Czytaj oryginał (ang.) |
| Best Momentum Stocks to Buy for October 14th |
IAG, DMAC and HIVE made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 14, 2024. |
zacks.com |
2024-10-14 15:00:18 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for October 14th |
HQI, CLPR, HIVE, DMAC and IAG have been added to the Zacks Rank #1 (Strong Buy) List on October 14, 2024. |
zacks.com |
2024-10-14 13:43:18 |
Czytaj oryginał (ang.) |
| DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia |
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced regulatory approval has been received to initiate a Phase 2 clinical trial with DM199, its proprietary recombinant serine protease, for the treatment of preeclampsia. The South African Health Products Regulatory Authority (SAHPRA) has issued approval to proceed with the planned two-part Phase 2 s. |
businesswire.com |
2024-10-09 12:27:00 |
Czytaj oryginał (ang.) |
| DiaMedica Therapeutics Upcoming Conference Participation |
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke and preeclampsia, announced today that management will be participating in the following investor conferences during September. HC Wainwright Global Investment Conference, September 9-11, New York – Management will present in person on Monday, September 9th at 3:00-3:30 PM ET and p. |
businesswire.com |
2024-09-04 20:15:00 |
Czytaj oryginał (ang.) |
| Are Medical Stocks Lagging DiaMedica Therapeutics (DMAC) This Year? |
Here is how DiaMedica Therapeutics, Inc. (DMAC) and Elutia Inc. (ELUT) have performed compared to their sector so far this year. |
zacks.com |
2024-08-01 14:42:06 |
Czytaj oryginał (ang.) |
| DiaMedica: Early 2025 Interim Futility Analysis Could Be A Major Inflection Point |
An interim futility analysis by the DSMB of DM199 for patients with AIS in the phase 2/3 ReMEDy2 trial is expected by Q1 of 2025. The global acute ischemic stroke therapeutics market size is expected to be worth $14 billion by 2032. Proof-of-concept data from a phase 2 study, using DM199 for the treatment of women with pregnancy complications, is expected 1st half of 2025. |
seekingalpha.com |
2024-07-11 18:48:34 |
Czytaj oryginał (ang.) |
| DiaMedica Therapeutics Announces $11.8 Million Private Placement |
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced that it has entered into definitive agreements to sell its common shares in a private placement with accredited investors. The transaction is expected to result in gross proceeds of $11.8 million. A placement agent was not used in connection with this private placement. Pursuant to the terms of t. |
businesswire.com |
2024-06-26 12:15:00 |
Czytaj oryginał (ang.) |
| DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia |
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced that it plans to expand its DM199 (rinvecalinase alfa; recombinant human tissue kallikrein-1 (rhKLK1)) clinical development program into preeclampsia. Preeclampsia is a life-threatening pregnancy-associated vascular disorder characterized by new onset hypertension with proteinuria, and/or end org. |
businesswire.com |
2024-06-26 12:00:00 |
Czytaj oryginał (ang.) |
| DiaMedica Therapeutics Inc. (DMAC) Q1 2024 Earnings Call Transcript |
DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q1 2024 Results Conference Call May 9, 2024 8:00 AM ET Company Participants Rick Pauls - President, CEO & Director Lorianne Masuoka - Chief Medical Officer Scott Kellen - CFO & Company Secretary Conference Call Participants Chase Knickerbocker - Craig-Hallum Thomas Flaten - Lake Street François Brisebois - Oppenheimer Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics First Quarter 2024 Conference Call. An audio recording of the webcast will be available shortly after the call today on DiaMedica's website at www.diamedica.com in the Investor Relations section. |
seekingalpha.com |
2024-05-11 20:49:05 |
Czytaj oryginał (ang.) |
| DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024 |
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its first quarter 2024 financial results will be released after the markets close on Wednesday, May 8th. DiaMedica will host a live conference call on Thursday, May 9th at 7:00 AM Central Time to provide a business update and discuss financial results. Confe. |
businesswire.com |
2024-05-02 12:55:00 |
Czytaj oryginał (ang.) |
| DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch |
DiaMedica (DMAC) rises 10% as it doses the first patient in the relaunch of its pivotal study evaluating the lead candidate, DM199, to treat acute ischemic stroke. |
zacks.com |
2024-04-18 15:10:27 |
Czytaj oryginał (ang.) |
| DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke |
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today announced the first patient being dosed in DiaMedica's relaunch of its pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the treatment of acute ischemic stroke. The company continues to work closely with its contract research organization (CRO), on re-engaging with study sites for the ReM. |
businesswire.com |
2024-04-17 20:08:00 |
Czytaj oryginał (ang.) |
| DiaMedica Therapeutics (DMAC) Loses -19.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner |
DiaMedica Therapeutics (DMAC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
zacks.com |
2024-04-15 14:36:10 |
Czytaj oryginał (ang.) |
| Wall Street's Favorite Penny Stocks? 7 Names That Could Make You Filthy Rich |
The bullish sentiment in the market is leading some investors to look at risk-on assets. Bitcoin may be an option, but for investors who prefer to stay in stocks, it may be time to look for some of the analysts' favorite penny stocks. |
investorplace.com |
2024-03-23 08:00:00 |
Czytaj oryginał (ang.) |
| DiaMedica Therapeutics Inc. (DMAC) Q4 2023 Earnings Call Transcript |
DiaMedica Therapeutics Inc. (DMAC) Q4 2023 Earnings Call Transcript |
seekingalpha.com |
2024-03-20 18:14:06 |
Czytaj oryginał (ang.) |
| DMAC Stock Earnings: DiaMedica Therapeutics Meets EPS for Q4 2023 |
DiaMedica Therapeutics (NASDAQ: DMAC ) just reported results for the fourth quarter of 2023. DiaMedica Therapeutics reported earnings per share of -14 cents. |
investorplace.com |
2024-03-19 23:53:17 |
Czytaj oryginał (ang.) |